Circulating Tumor Cells Predict Survival Benefit From Treatment In Metastatic Castration-Resistant Prostate Cancer
November 10th, 2008 Posted in prostate cancerIn the October 1, 2008 issue of Clinical Cancer Research, Dr. Johann de Bono and colleagues presented exciting data indicating that circulating tumor cells (CTC) predict overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). CTC using the commercially available CellSearch is approved by the FDA as a prognostic indicator for patients with metastatic breast, prostate, and colorectal cancer. CTC have been reported to correlate with clinical outcomes in patients with CRPC.